Purpose. Determining long-term effects of rheohaemapheresis on the dry form of age-related macular degeneration. Methods. This study evaluates 19 patients, average age of 67.6 years, treated with rheohaemapheresis and 18 patients, average age of 72.8 years, comprising the control group. Minimum follow up period was 3.5 years. Each treated patient received a series of 8 sessions of rheohaemapheresis of 1.5 plasma volumes within 10 weeks. We measured the drusenoid pigment epithelium detachment (DPED), best-corrected visual acuity (BCVA), electroretinography (ERG), and rheological parameters. Results. In the treatment group, the baseline BCVA was 0.74 (0.36-1.0) 95% CI and BCVA after 3.5 years was 0.79 (0.41-1.0) 95% CI (P = 0.726). In the control group, the baseline BCVA was 0.71 (0.15-1.0) 95% CI and BCVA after 3.5 years decreased to 0.7 (0.32-0.87) 95% CI (P = 0.031). Baseline DPED was 6.78 ± 3.79 mm(2); after 3.5 years, it decreased to 4.13 ± 3.84 mm(2) (P < 0.001). In the control group, the baseline DPED was 4.09 ± 3.48 mm(2); after 3.5 years, it increased to 6.69 ± 4.2 mm(2) (P = 0.001). We noted increasing levels of positive wave peaking at 50 milliseconds (P50) after treatment (P = 0.022) and a stable amplitude of photopic responses of treated patients. Conclusion. Over the long term, rheohaemapheresis reduced the DPED, improved the function of photoreceptors, and prevented the decline of BCVA.

2nd Department of Internal Medicine Haematology Charles University Medical Faculty and Faculty Hospital Hradec Králové Czech Republic

Department of Gerontology and Metabolic Care Charles University Medical Faculty and Faculty Hospital Hradec Králové Czech Republic

Department of Ophthalmology Charles University Medical Faculty and Faculty Hospital Hradec Králové Czech Republic

Department of Ophthalmology University Hospital Ostrava Czech Republic

Zobrazit více v PubMed

Seddon JM, Chen CA. The epidemiology of age-related macular degeneration. International Ophthalmology Clinics. 2004;44(4):17–39. PubMed

Klein R, Meuer SM, Knudtson MD, Iyengar SK, Klein BEK. The epidemiology of retinal reticular drusen. American Journal of Ophthalmology. 2008;145(2):317.e1–326.e1. PubMed PMC

Klingel R, Fassbender C, Fassbender T, Erdtracht B, Berrouschot J. Rheopheresis: rheologic, functional, and structural aspects. Therapeutic Apheresis. 2000;4(5):348–357. PubMed

Ferris FL, III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Archives of Ophthalmology. 1984;102(11):1640–1642. PubMed

Klingel R, Fassbender C, Faßbender T, Göhlen B. Clinical studies to implement rheopheresis for age-related macular degeneration guided by evidence-based-medicine. Transfusion and Apheresis Science. 2003;29(1):71–84. PubMed

Borberg H, Tauchert M. Rheohaemapheresis of ophthalmological diseases and diseases of the microcirculation. Transfusion and Apheresis Science. 2006;34(1):41–49. PubMed

Zion IB, Harris A, Siesky B, Shulman S, McCranor L, Garzozi HJ. Pulsatile ocular blood flow: relationship with flow velocities in vessels supplying the retina and choroid. British Journal of Ophthalmology. 2007;91(7):882–884. PubMed PMC

Rencová E, Bláha M, Studnička J, et al. Haemorheopheresis could block the progression of the dry form of age-related macular degeneration with soft drusen to the neovascular form. Acta Ophthalmologica. 2011;89(5):463–471. PubMed

Fiala JC. Reconstruct: a free editor for serial section microscopy. Journal of Microscopy. 2005;218(1):52–61. PubMed

Marmor MF, Holder GE, Seelinger MW, Yamamoto S. Standard for clinical electroretinography (2004 update) Documenta Ophthalmologica. 2004;108(2):107–114. PubMed

Marmor MF, Holder GE, Porciatti V, Trick GL, Zrenner E, Barber C. Guidelines for basic pattern electroretinography: recommendations by the international society for clinical electrophysiology of vision. Documenta Ophthalmologica. 1995;91(4):291–298. PubMed

Hood DC, Bach M, Brigell M, et al. ISCEV guidelines for clinical multifocal electroretinography (2007 edition) Documenta Ophthalmologica. 2008;116(1):1–11. PubMed PMC

Pulido JS, Anderson WB, Jr., Flynn JT, Lichter PR, Sanders D. Multicenter prospective, randomized, double-masked, placebo-controlled study of rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. Transactions of the American Ophthalmological Society. 2002;100:85–107. PubMed PMC

Pulido JS, Winters JL, Boyer D. Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results. Transactions of the American Ophthalmological Society. 2006;104:221–229. PubMed PMC

Blaha M, Rencova E, Langrova H, et al. Rheohaemapheresis in the treatment of nonvascular age-related macular degeneration. Atherosclerosis Supplements. 2013;14(1):179–184. PubMed

Sikorski BL, Bukowska D, Kaluzny JJ, Szkulmowski M, Kowalczyk A, Wojtkowski M. Drusen with accompanying fluid underneath the sensory retina. Ophthalmology. 2011;118(1):82–92. PubMed

Klein R, Klein BEK, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration. The Beaver Dam Eye study. Ophthalmology. 2007;114(2):253–262. PubMed

Khanifar AA, Koreishi AF, Izatt JA, Toth CA. Drusen ultrastructure imaging with spectral domain optical coherence tomography in age-related macular degeneration. Ophthalmology. 2008;115(11):1883.e1–1890.e1. PubMed PMC

Bláha M, Krejsek J, Bláha V, et al. Selectins and monocyte chemotactic peptide as the markers of atherosclerosis aktivity. Physiological Research. 2004;53(3):273–278. PubMed

Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(21):11877–11882. PubMed PMC

Bláha M, Skorepová M, Masín V, et al. The role of erythrocytapheresis in secondary erythrocytosis therapy. Clinical Hemorheology and Microcirculation. 2002;26(4):273–275. PubMed

Soluble endoglin as a biomarker of successful rheopheresis treatment in patients with age-related macular degeneration

Preservation of the Photoreceptor Inner/Outer Segment Junction in Dry Age-Related Macular Degeneration Treated by Rheohemapheresis

Dynamics of blood count after rheohemapheresis in age-related macular degeneration: possible association with clinical changes